Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components

A phase I dose-escalation study of IMGN388 in patients with solid tumors.

(2017) D. S. Thompson et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibody-based therapeutics to watch in 2011

(2011) Janice M. Reichert   mAbs

Research and development of next generation of antibody-based therapeutics

(2010) Jing Li et al.   ACTA PHARMACOLOGICA SINICA

Tumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects

(2010) Hiroshi Maeda   BIOCONJUGATE CHEMISTRY

Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance

(2010) Y. V. Kovtun et al.   CANCER RESEARCH

Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

(2010) J. R. Junutula et al.   CLINICAL CANCER RESEARCH

Antibody–drug conjugates: targeted drug delivery for cancer

(2010) Stephen C Alley et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Recent Progress in Research on Ribosome Inactivating Proteins

(2010) T. Ng et al.   CURRENT PROTEIN & PEPTIDE SCIENCE

Inotuzumab ozogamicin as novel therapy in lymphomas

(2010) Bryan Y Wong et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Investigational antibody-drug conjugates for hematological malignancies

(2010) Andrew G Polson et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

(2010) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules

(2010) M. Lopus et al.   MOLECULAR CANCER THERAPEUTICS

Denileukin diftitox—a step towards a 'magic bullet' for CTCL

(2010) Marshall E. Kadin et al.   Nature Reviews Clinical Oncology

Antibody–drug conjugates for cancer: poised to deliver?

(2010) Bethan Hughes   NATURE REVIEWS DRUG DISCOVERY

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ribosome-Inactivating Proteins: From Plant Defense to Tumor Attack

(2010) Maddalena de Virgilio et al.   Toxins

Targeted Toxins in Brain Tumor Therapy

(2010) Yan Michael Li et al.   Toxins

Toxin-Based Therapeutic Approaches

(2010) Assaf Shapira et al.   Toxins

A Phase II Trial of Denileukin Diftitox in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

(2009) Margie Gerena-Lewis et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody−Maytansinoid Conjugates

(2009) Hans K. Erickson et al.   BIOCONJUGATE CHEMISTRY

Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies

(2009) Laurent Ducry et al.   BIOCONJUGATE CHEMISTRY

Preclinical Assessment of an Anti-EpCAM Immunotoxin: Locoregional Delivery Provides a Safer Alternative to Systemic Administration

(2009) Jennifer Brown et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection

(2009) A. G. Polson et al.   CANCER RESEARCH

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo

(2009) H. Ikeda et al.   CLINICAL CANCER RESEARCH

Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma

(2009) A. M. Al-Katib et al.   CLINICAL CANCER RESEARCH

A Review of Studies on Targeting Interleukin 4 Receptor for Central Nervous System Malignancy

(2009) Sachin Puri et al.   CURRENT MOLECULAR MEDICINE

INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model

(2009) R. Graeser et al.   INVESTIGATIONAL NEW DRUGS

Novel Peptide Linkers for Highly Potent Antibody−Auristatin Conjugate

(2008) Svetlana O. Doronina et al.   BIOCONJUGATE CHEMISTRY

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

Recent Trends in Targeted Anticancer Prodrug and Conjugate Design

(2008) Yashveer Singh et al.   CURRENT MEDICINAL CHEMISTRY

Monoclonal Antibodies as Innovative Therapeutics

(2008) Janice Reichert   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

The effect of dendrimers on the pharmacodynamic and pharmacokinetic behaviors of non-covalently or covalently attached drugs

(2008) Yiyun Cheng et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY

An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes

(2008) M. Onda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs

(2007) Ravi V. J. Chari   ACCOUNTS OF CHEMICAL RESEARCH